Nicotinamide riboside for peripheral nervous system diseases

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Oct 2019: Trial registered, NCT04112641
  2. 19 Feb 2020: Trial started, NCT04112641

The trials

NCT04112641: NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy

State
Under way
Phase
Phase 2
People
48 planned
Started
19 Feb 2020
Primary completion
28 Jun 2027
Arms
Nicotinamide Riboside (NIAGEN)
Results
None posted
  1. 2 Oct 2019: Trial registered
  2. 19 Feb 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as Nicotinamide ribonucleoside.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.